These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 31085765

  • 1. Germline and Somatic Mutations in Prostate Cancer for the Clinician.
    Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS.
    J Natl Compr Canc Netw; 2019 May 01; 17(5):515-521. PubMed ID: 31085765
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness.
    Pritchard CC.
    Can J Urol; 2019 Oct 01; 26(5 Suppl 2):24-26. PubMed ID: 31629422
    [Abstract] [Full Text] [Related]

  • 4. Genetic testing for hereditary prostate cancer: Current status and limitations.
    Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, Llor X, Hofstatter E, Shuch B.
    Cancer; 2018 Aug 01; 124(15):3105-3117. PubMed ID: 29669169
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    Wei J, Yang W, Shi Z, Lu L, Wang Q, Resurreccion WK, Engelmann V, Zheng SL, Hulick PJ, Cooney KA, Isaacs WB, Helfand BT, Lu J, Xu J.
    Prostate; 2021 Sep 01; 81(13):1002-1008. PubMed ID: 34254341
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Germline and somatic mutations in prostate cancer: Implications for treatment.
    Chalker C, Chun B, Sokolova AO.
    Curr Probl Cancer; 2024 Jun 01; 50():101101. PubMed ID: 38718711
    [Abstract] [Full Text] [Related]

  • 10. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
    Freedland SJ, Aronson WJ.
    Urol Oncol; 2017 Aug 01; 35(8):536-537. PubMed ID: 28623070
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S, Cardoso M, Paulo P, Pinheiro M, Pinto P, Santos C, Pinto C, Peixoto A, Henrique R, Teixeira MR.
    Fam Cancer; 2016 Jan 01; 15(1):111-21. PubMed ID: 26289772
    [Abstract] [Full Text] [Related]

  • 13. Prostate Cancer Screening in a New Era of Genetics.
    Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS.
    Clin Genitourin Cancer; 2017 Dec 01; 15(6):625-628. PubMed ID: 28697982
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG, Johnson AM, Hanson KL, Dayno ME, Kapron AL, Stoffel EM, Cooney KA.
    Cancer; 2017 Oct 15; 123(20):3925-3932. PubMed ID: 28657667
    [Abstract] [Full Text] [Related]

  • 16. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
    Marino F, Totaro A, Gandi C, Bientinesi R, Moretto S, Gavi F, Pierconti F, Iacovelli R, Bassi P, Sacco E.
    Prostate Cancer Prostatic Dis; 2023 Dec 15; 26(4):655-664. PubMed ID: 36434163
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Germline testing in those at risk of prostate cancer.
    Carroll PR, Witte JS, Parsons JK.
    Can J Urol; 2019 Oct 15; 26(5 Suppl 2):31-33. PubMed ID: 31629425
    [Abstract] [Full Text] [Related]

  • 19. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB, Kirichek AA, Filippova MG, Savinkova AV, Khalmurzaev OA, Lyubchenko LN.
    Urologiia; 2019 Dec 15; (5):79-85. PubMed ID: 31808637
    [Abstract] [Full Text] [Related]

  • 20. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA, Baig MK, Milewski B, Keywan C, Guarino M, Petrelli N.
    Ann Surg Oncol; 2016 May 15; 23(5):1729-35. PubMed ID: 26727920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.